I agree that the poster’s story is not matching up. His initial post had a specific price tag and date, of which the date was wrong (no announcement yesterday) and an explanation for the price was not offered. His initial posts were simple and then became more elaborate, with deeper explanations each time.

Lastly, the statement that BP doesn’t believe leronlimab will work in any other indication, such as cancer, is ridiculous. I’m not stating that leronlimab will work in those indications based on the preclinical trials, but any BP company with similar results would be exited to start phase 2 trials. This aspect of the posters formation makes me question their motive. Why claim that you bought CYDY at the lowest prices, that BP likes the HIV indication, but then state that BP believes leronlimab will not work for any other indication? At this point, leronlimab has an equal chance of working as an other drug in phase 2 for cancer and GvHD.